Victory Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-7,016
| Closed | -$264K | – | 2856 |
|
|
2021
Q1 | $264K | Sell |
7,016
-835,415
| -99% | -$20.8M | ﹤0.01% | 2446 |
|
|
2020
Q4 | $14.3M | Buy |
+842,431
| New | +$10.6M | 0.02% | 1009 |
|
|
2020
Q2 | – | Sell |
-11,852
| Closed | -$26K | – | 3634 |
|
|
2020
Q1 | $26K | Buy |
+11,852
| New | +$50.3K | ﹤0.01% | 3024 |
|
|
2019
Q4 | – | Sell |
-5,390
| Closed | -$21K | – | 3604 |
|
|
2019
Q3 | $21K | Buy |
+5,390
| New | +$29.6K | ﹤0.01% | 3033 |
|
|
2018
Q3 | – | Sell |
-1,102,760
| Closed | -$17.4M | – | 1928 |
|
|
2018
Q2 | $17.4M | Buy |
1,102,760
+35,670
| +3% | +$622K | 0.04% | 634 |
|
|
2018
Q1 | $18.3M | Buy |
1,067,090
+142,900
| +15% | +$2.79M | 0.04% | 605 |
|
|
2017
Q4 | $20.3M | Buy |
924,190
+391,550
| +74% | +$12.6M | 0.04% | 576 |
|
|
2017
Q3 | $21.8M | Sell |
532,640
-133,800
| -20% | -$4.2M | 0.05% | 557 |
|
|
2017
Q2 | $20.1M | Buy |
666,440
+149,340
| +29% | +$4.66M | 0.05% | 575 |
|
|
2017
Q1 | $18.7M | Buy |
517,100
+41,717
| +9% | +$1.84M | 0.04% | 597 |
|
|
2016
Q4 | $23.8M | Sell |
475,383
-113,350
| -19% | -$5.96M | 0.06% | 523 |
|
|
2016
Q3 | $30.9M | Buy |
+588,733
| New | +$28.1M | 0.09% | 405 |
|
Victory Capital Management's FPRX Position: Q2 2021 in Review
Victory Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 7,016 shares — an estimated $264K sold.
Victory Capital Management first reported a position in FPRX in Q3 2016 and held it in 12 quarters. The position peaked at $30.9M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Victory Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Victory Capital Management sold 7,016 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $264K.
- Victory Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 12 quarters.
- Victory Capital Management's Five Prime Therapeutics, Inc. position peaked at $30.9M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Victory Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.